Abbreviations
BMA, bone-modifying agents; CT, computed tomography; D/C, discontinue; FDA, US Food and Drug Administration; IV, intravenous; MRI, magnetic resonance imaging; ONJ, osteonecrosis of the jaw; subcut, subcutaneous
Source
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH; American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of BMAs in metastatic breast cancer. J Clin Oncol. 2011 Mar 20;29(9):1221-1227. Epub 2011 Feb 22.
Disclaimer This resource is a practice tool for physicians based on an ASCO®
guideline and this tool are not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. This tool does not recommend any particular product or course of medical treatment. Use of the practice guideline and this resource is voluntary. The full practice guideline and additional information are available at http://www.asco.org/guidelines. Copyright © 2011 by American Society of Clinical Oncology ®
practice guideline. The practice . All rights reserved. BMA091109
5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2011 All rights reserved
